Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?
TheFly reported on June 16 that BIOA announced the dosing of the first participant in QUELL-CV, a Phase 2 proof-of-concept study evaluating BGE-102.









